Ravasio, Roberto, Holly Cranmer, Izzie Kearns, Raffaella Viti, and Simone Corinti. “Cost-Utility Analysis of Brigatinib Compared to Alectinib in the Treatment of ALK-Positive NSCLC in Patients Previously Not Treated With an ALK Inhibitor”. AboutOpen 9, no. 1 (October 24, 2022): 92–104. Accessed April 20, 2024. https://journals.aboutscience.eu/index.php/aboutopen/article/view/2450.